
News|Articles|December 5, 2025
Executive Summary: Mastering Nitrosamines Analysis With Streamlined LC-MS/MS Solutions
Author(s)SCIEX
Nitrosamine contamination in pharmaceuticals has become a major regulatory concern due to their potent carcinogenicity, requiring ultra-trace-level detection to ensure patient safety. Advanced LC-MS/MS workflows provide the necessary sensitivity, selectivity, and robustness to accurately quantify nitrosamine drug substance-related impurities (NDSRIs), even within complex pharmaceutical matrices. Case studies with betahistine, orphenadrine, and chloropyramine demonstrate how streamlined LC-MS/MS strategies can reliably detect and confirm nitrosamine impurities well below regulatory thresholds.
Trending on Pharmaceutical Technology
1
What Jideytro's Approval Means for Drug Developers
2
Q&A : Brent Wilhelm on Supply Chains and Historical Demand Data
3
PharmTech Weekly Roundup—July 24, 2026
4
Midyear 2026 Check-In: AI Investment Skipped Pharma's Costliest Operational Problem
5